← HeartSciences Inc. (HSCS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
HeartSciences Inc. (HSCS)
Finance Services · market cap $22M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-21 (est.)
Earnings
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-21 (est.)Earningsimp 5/10
- 2027-03-31 (est.)Phase 2 · Empagliflozinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Maraviroc | Phase 2 | Primary Graft Dysfunction |
| Perhexiline | Phase 2 | Chronic Heart Failure |
| Beta adrenergic blockers | Phase 3 | Cardiovascular Diseases |
| Sildenafil Citrate | Phase 3 | Pulmonary Fibrosis |
| Betamethasone | Phase 3 | Pregnancy |
| Glycine Buffer | Phase 2 | Cystic Fibrosis |
| Amino Acid infusion | Phase 2 | Acute Kidney Injury |
| MPC Intramyocardial Injection | Phase 2 | Heart Failure |
| Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training | Phase 2 | Peripheral Arterial Disease |
| Standard medical therapy | Phase 3 | Heart Failure |
| Levofloxacin | Phase 2 | Sarcoidosis; Antimycobacterial Therapy |
| BIO-11006 Inhalation Solution | Phase 2 | COPD |
| Secondary Prophylaxis | Phase 3 | Rheumatic Heart Disease |
| Atomoxetine | Phase 2 | Sleep Apnea |
| Dapagliflozin | Phase 2 | Chronic Kidney Diseases |
| Empagliflozin | Phase 2 | Obesity |
| Chelation therapy | Phase 2 | Anemia (Iron-Loading) |
| Anakinra | Phase 2 | Heart Failure With Normal Ejection Fraction |
| Eszopiclone | Phase 3 | Sleep Apnea |
| Epi-743 | Phase 2 | Methylmalonic Aciduria and Homocystinuria,Cblc Type |
Price & technical context
3-month
+32.2%
6-month
+37.6%
12-month
-5.7%
52-wk range
$1.67–$5.20
vs 50-day MA
-26.0%
vs 200-day MA
-1.3%
Realized vol
103.4%
Max drawdown
-70.9%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HSCS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.